for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arcturus Therapeutics Ltd

ARCT.OQ

Latest Trade

9.90USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

4.11

 - 

15.49

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Arcturus Therapeutics Reports Q3 Loss Per Share Of $0.56

Nov 7 (Reuters) - Arcturus Therapeutics Ltd <ARCT.O>::ARCTURUS THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.56.Q3 EARNINGS PER SHARE ESTIMATE $-0.36 -- REFINITIV IBES DATA.IND APPLICATION FOR ARCT-810, A TREATMENT OF ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY, IS ON TRACK FOR Q1 2020 FILING.AT SEPTEMBER 30, 2019, ARCTURUS HAD CASH AND CASH EQUIVALENTS TOTALING $74.2 MILLION.

Arcturus Therapeutics Q2 Loss Per Share $0.07

Aug 15 (Reuters) - Arcturus Therapeutics Ltd <ARCT.O>::ARCTURUS THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.Q2 LOSS PER SHARE $0.07.Q2 EARNINGS PER SHARE ESTIMATE $-0.64 -- REFINITIV IBES DATA.AT JUNE 30, 2019, CO HAD CASH AND CASH EQUIVALENTS TOTALING $55.8 MILLION.

Arcturus Therapeutics Announces Additional Registered Direct Offering Of Common Stock

Aug 2 (Reuters) - Arcturus Therapeutics Ltd <ARCT.O>::ARCTURUS THERAPEUTICS ANNOUNCES $2.3 MILLION ADDITIONAL REGISTERED DIRECT OFFERING OF COMMON STOCK.AGREEMENT WITH INSTITUTIONAL INVESTOR FOR PURCHASE & SALE IN OFFERING OF 200,000 SHARES OF COMMON STOCK AT $11.50 PER SHARE.INTENDS TO USE PROCEEDS FROM OFFERING TO FUND CONTINUED RESEARCH AND DEVELOPMENT INITIATIVES IN CONNECTION WITH ITS PRODUCT PIPELINE.

Arcturus Therapeutics Says Co & Curevac Terminated Co-Development And Co-Commercialization Agreement Dated Jan 1, 2018

July 29 (Reuters) - Arcturus Therapeutics Ltd <ARCT.O>::ARCTURUS THERAPEUTICS LTD - ON JULY 26, CO & CUREVAC TERMINATED CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT DATED JAN 1, 2018.ARCTURUS THERAPEUTICS LTD - CUREVAC AGREED TO MAKE A ONE-TIME PAYMENT TO CO OF $4 MILLION IN CONSIDERATION FOR TERMINATION.ARCTURUS THERAPEUTICS SAYS AMENDED DEVELOPMENT AND OPTION AGREEMENT WITH CUREVAC AG - SEC FILING.ARCTURUS THERAPEUTICS LTD - AMENDMENT REDUCES OVERALL NUMBER OF MAXIMUM TARGETS TO BE RESERVED AND LICENSED FROM 15 TO 10 TARGETS.ARCTURUS THERAPEUTICS LTD - AMENDMENT MODIFIES TIME PERIOD DURING WHICH CUREVAC MAY SELECT POTENTIAL TARGETS TO BE LICENSED FROM CO.

Arcturus Therapeutics Receives Orphan Drug Designation From The U.S. FDA For Arct-810, For Treatment Of Ornithine Transcarbamylase (Otc) Deficiency

June 27 (Reuters) - Arcturus Therapeutics Ltd <ARCT.O>::ARCTURUS THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FROM THE U.S. FDA FOR ARCT-810, FOR TREATMENT OF ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY.

Arcturus Therapeutics Holdings Files For Mixed Shelf Of Up To $100 Million – SEC Filing

June 21 (Reuters) - Arcturus Therapeutics Ltd <ARCT.O>::ARCTURUS THERAPEUTICS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING.

Ultragenyx And Arcturus Expand Existing Research License Agreement To Develop Additional Nucleic Acid Therapies For Rare Diseases

June 19 (Reuters) - Arcturus Therapeutics Ltd <ARCT.O>::ULTRAGENYX AND ARCTURUS THERAPEUTICS EXPAND EXISTING RESEARCH COLLABORATION AND LICENSE AGREEMENT TO DEVELOP ADDITIONAL NUCLEIC ACID THERAPIES FOR RARE DISEASES.ULTRAGENYX PHARMACEUTICAL INC - 30 MILLION OF UPFRONT PAYMENTS TO ARCTURUS, INCLUDING $6 MILLION CASH FOR COLLABORATION AGREEMENT AMENDMENT.ULTRAGENYX PHARMACEUTICAL INC - $30 MILLION OF UPFRONT PAYMENTS TO ARCTURUS, INCLUDING $24 MILLION EQUITY INVESTMENT AT $10 PER SHARE.ULTRAGENYX PHARMACEUTICAL INC - ULTRAGENYX BECOMES ARCTURUS' LARGEST SHAREHOLDER.ULTRAGENYX PHARMACEUTICAL - ARCTURUS IS ENTITLED TO PRECLINICAL, CLINICAL, REGULATORY, AND SALES MILESTONE PAYMENTS FOR PRODUCT DEVELOPED UNDER COLLABORATION.ULTRAGENYX PHARMACEUTICAL INC - KARAH PA KARAH PARSCHAUER, J.D., GENERAL COUNSEL OF CO, JOINING ARCTURUS' BOARD.ULTRAGENYX PHARMACEUTICAL - CERTAIN EARLY-STAGE MILESTONE PAYMENTS ARE REDUCED UNDER AMENDED LICENSE AGREEMENT.ULTRAGENYX PHARMACEUTICAL INC - CEO OF CO JOINING AS ARCTURUS BOARD OBSERVER.ULTRAGENYX PHARMACEUTICAL INC - UNDER AMENDED LICENSE AGREEMENT, TOTAL POTENTIAL MILESTONE PAYMENTS ARE INCREASED DUE TO EXPANDED NUMBER OF TARGETS..ULTRAGENYX PHARMACEUTICAL INC - ARCTURUS IS ALSO ENTITLED TO REIMBURSEMENT OF RELATED RESEARCH EXPENSES AND ROYALTIES ON COMMERCIAL SALES..ULTRAGENYX PHARMACEUTICAL - COS EXPANDED COLLABORATION TO DISCOVER & DEVELOP MRNA, DNA & SIRNA THERAPEUTICS FOR UP TO 12 RARE DISEASE TARGETS.

Arcturus Therapeutics Posts Q1 Loss Per Share of $0.68

May 13 (Reuters) - Arcturus Therapeutics Ltd <ARCT.O>::ARCTURUS THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.Q1 LOSS PER SHARE $0.68.Q1 EARNINGS PER SHARE ESTIMATE $-0.58 -- REFINITIV IBES DATA.REMAINS ON TRACK TO REDOMICILE FROM AN ISRAELI LIMITED COMPANY TO A DELAWARE CORPORATION.QTRLY COLLABORATION REVENUE WAS $4.4 MILLION VERSUS $2.4 MILLION.Q1 REVENUE VIEW $3.1 MILLION -- REFINITIV IBES DATA.

Arcturus Therapeutics Q4 Loss Per Share $0.10

March 18 (Reuters) - Arcturus Therapeutics Ltd <ARCT.O>::ARCTURUS THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND YEAR END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.10.Q4 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA.APPOINTED ANDREW SASSINE AS CHIEF FINANCIAL OFFICER.FOR Q4 OF 2018, REPORTED REVENUE OF $7.6 MILLION, COMPARED WITH $2.0 MILLION DURING Q4 OF 2017.CASH, CASH EQUIVALENTS, AND INVESTMENTS TOTALED $36.7 MILLION AS OF DECEMBER 31, 2018.ARCTURUS THERAPEUTICS - BASED ON CURRENT PROJECTIONS, CO'S CURRENT CASH POSITION IS EXPECTED TO BE SUFFICIENT TO SUPPORT OPERATIONS THROUGH EARLY Q1 OF 2020.

Arcturus Therapeutics Reassumes Full Worldwide Rights To Arct-810, A Clinical Development Candidate For Ornithine Transcarbamylase Deficiency

Feb 11 (Reuters) - Arcturus Therapeutics Ltd <ARCT.O>::ARCTURUS THERAPEUTICS REASSUMES FULL WORLDWIDE RIGHTS TO ARCT-810, A CLINICAL DEVELOPMENT CANDIDATE FOR ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY.ARCTURUS THERAPEUTICS LTD - CUREVAC ELECTED NOT TO CONTINUE ITS OBLIGATIONS FOR PRECLINICAL DEVELOPMENT OF ARCT-810.ARCTURUS THERAPEUTICS LTD - ARCT-810 WAS PREVIOUSLY SUBJECT TO A 50/50 COLLABORATION BETWEEN ARCTURUS AND CUREVAC AG.ARCTURUS THERAPEUTICS LTD - PRECLINICAL DEVELOPMENT PROGRAM FOR ARCT-810 INCLUDING IND ENABLING STUDIES, REMAINS ON TRACK.ARCTURUS THERAPEUTICS LTD - PLANNING TO FILE AN IND FOR ARCT-810 WITH U.S. FOOD AND DRUG ADMINISTRATION IN Q4 OF 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up